| Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer (NCT03914612) | National Cancer Institute (NCI) | 2019-08-22 |
| Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancers (NCT05049538) | M.D. Anderson Cancer Center | 2019-06-18 |
| Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone (NCT03660826) | National Cancer Institute (NCI) | 2018-09-27 |
| Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer (NCT03422198) | University of Utah | 2018-02-02 |
| Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer (NCT02728258) | NRG Oncology | 2016-09-16 |
| Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer (NCT02874430) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2016-06-08 |
| Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol (NCT02501954) | Women's Cancer Care Associates, LLC | 2015-03-01 |
| Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery (NCT02315469) | NRG Oncology | 2015-02-10 |
| TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors (NCT02142803) | National Cancer Institute (NCI) | 2014-05-20 |
| Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer (NCT02112552) | Albert Einstein College of Medicine | 2014-04-10 |
| Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer (NCT02065687) | Gynecologic Oncology Group | 2014-03-17 |
| Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers (NCT02020707) | Mayo Clinic | 2014-02-24 |
| Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer (NCT01935973) | National Cancer Institute (NCI) | 2013-09-30 |
| Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer (NCT01935934) | National Cancer Institute (NCI) | 2013-05-08 |
| PET/CT and Lymph Node Mapping in Finding Lymph Node Metastasis in Patients With High-Risk Endometrial Cancer (NCT01737619) | M.D. Anderson Cancer Center | 2013-04-03 |
| Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer (NCT01642082) | Gynecologic Oncology Group | 2012-09-01 |
| Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer (NCT01225887) | Gynecologic Oncology Group | 2011-10-01 |
| Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer (NCT01440998) | National Cancer Institute (NCI) | 2011-09-20 |
| Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer (NCT01307631) | National Cancer Institute (NCI) | 2011-03-01 |
| Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer (NCT01132820) | National Cancer Institute (NCI) | 2010-06-01 |
| Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer (NCT01344837) | Gynecologic Oncology Group | 2010-01-01 |
| Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer (NCT01005329) | National Cancer Institute (NCI) | 2009-11-06 |
| Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer (NCT00977574) | National Cancer Institute (NCI) | 2009-09-14 |
| Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer (NCT01010126) | National Cancer Institute (NCI) | 2009-09-08 |
| Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer (NCT00942357) | Gynecologic Oncology Group | 2009-06-29 |
| Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer (NCT00807768) | Gynecologic Oncology Group | 2009-03-23 |
| Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer (NCT00575952) | Gynecologic Oncology Group | 2008-01-17 |
| Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer (NCT00478426) | National Cancer Institute (NCI) | 2007-04-30 |
| Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer (NCT00005840) | Gynecologic Oncology Group | 2000-07-01 |
| Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer (NCT00005830) | Gynecologic Oncology Group | 2000-07-01 |
| Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer (NCT00006011) | Gynecologic Oncology Group | 2000-07-01 |